Conference Reports for NATAP

62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back

Characterization of HCV Resistance from a Multiple Dose Clinical Trial of GS-5885, a Novel HCV NS5A Inhibitor       Reported by Jules Levin AASLD Nov 5-8 2011 SF   KA Wong, A Worth, R Martin, E Svarovskaia, DM Brainard, JG McHutchison, MD Miller, H Mo Gilead Sciences, Foster City, CA United States